A similar trend was found in earlier studies, although the magnitude of our finding is quite significant: 45.5% versus 31% 49 and 28.1%. 38 This may be due to fear of adverse effects and unavailability of certain evidence-based medicines, such as β-blockers licensed for heart failure, angiotensin-receptor blockers, and vasodilator combinations, in our setting.
← all excerpts
Drug-Therapy Problems and Predictors among Hospitalized Heart-Failure Patients: A Prospective Observational Study.
1
—
—